Regrettably PAA mandatorily has to raise funds Floating , they...

Regrettably PAA mandatorily has to raise funds Floating , they cannot breach the ASX 2 x Q of Operating Capital ... they only just skimmed in with the last Quarterly. Plus PAA has increased staff significantly.

What type of Non Dilutive Funding do you propose? Loan? Remember PAA has no Income BUT that could change in in the coming months , now with FDA ODD approval MPL can be prescribed. That's why having packaging ready early can be crucial.

Our current (Poor ) competitor is retailing their MND Treatment for between $10,000 and $14,000 per month

PAA are manufacturing 750,000 (3 x 250k) commercial GMP grade tablets currently....

The new BOD understand the importance of the Regulatory Process and Governance ,,, they need a week or 2 to get their feet under the desk but I would be instigating a Commercial Valuation of the Company ( That's a 2/3 week process) so getting that underway is as simple as employing the Valuation Company,, phone call and email , it's the Valuers Core Business,,,, Then I would instruct the Market that the New BOD believe the Company is and has been Historically undervalued and that the Valuation is underway for the benefit of current SH and future Investors...

Been doing this a while and "Investors Love to Discover an Undervalued Asset" and from where I'm sitting PAA is chronically undervalued.

Human Cancer $100m ' There is not a single ASX Oncology Company that has completed a Human Phase I Trial Under $100m"
If you then extrapolate the Olivia Newton John Cancer Foundation Clinical Trial 28 of 30 Human Cancers responded positively to MPL $300m
K9 Cancer , well Aratana sold to Elanco for their K9 Lymphoma Treatment $245m USD
MND , I'll go with MT on $500m after Phase II Positive data $1B
Covid , simple Oral Tablets reducing viral load by 95% in 72 hours and may possibly be the CURE for Long Covid $2B
HVTL-1 Infections $200m

I'm no valuer but I would shout everyone lunch if it came in under $300m / $400m from the Professionals as most of the Valuation is by Comparison of other ASX listed Biotechs in the same field ,,,

Best make that call and then Tell the Market the valuation is on its way ,,, then deliver the Valuation as if it was Christmas

Every Market interaction must be maximised ,,, PAAs Achilles Heel was always Market Messaging surrounding Value $$$$$$ look at what MT actually achieved ,,, he informed the Market about Value ..... Research is critical but it's managements duty to impart that successful Trialing and Positive data actually means "Enterprise Risk Reduction" we are closer to Commercialisation than ever before ........ NZT